Oshkosh Corporation topped revenue expectations in its latest quarter, but profit fell short as tariffs and cost pressures squeezed margins. The specialty vehicle maker's 2026 outlook balances targeted growth in some segments against persistent challenges in construction markets.
Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
Mid-cap companies offer a compelling blend of established operations and growth runway, but they navigate a perilous landscape between industry titans and agile disruptors. We examine three stocks where investor optimism may be overlooking critical challenges.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.
While small-cap stocks can offer unique growth opportunities away from Wall Street's spotlight, their inherent risks demand careful scrutiny. We examine three companies where valuation concerns and competitive pressures suggest caution may be warranted.
Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.
Profitability is a crucial starting point for investors, but it's not a guaranteed shield against market shifts. As competition evolves, today's cash generators can become tomorrow's laggards. We analyze three companies with strong margins to separate resilient growth from potential stagnation.
While the allure of finding the next undervalued gem is strong, some stocks trading at low multiples may be cheap for a reason. We examine three companies where fundamental challenges could outweigh their seemingly attractive valuations.
As earnings season concludes, we analyze the performance of construction and maintenance services stocks. While the sector showed overall strength, WillScot Mobile Mini faced headwinds, contrasting with standout results from peers like Comfort Systems.
As earnings season winds down, the waste management sector reveals a tale of resilience and regulatory reckoning. While Enviri's results disappointed, others like Perma-Fix surprised to the upside, highlighting the industry's complex dance between steady demand and economic sensitivity.
As earnings season winds down, the construction and maintenance services sector showed resilience. Great Lakes Dredge & Dock posted solid results despite a revenue miss, while peers like Primoris soared. We analyze the key drivers and what's next for these industrial players.
The third-quarter earnings season reveals a tale of two strategies in the property services sector. While Opendoor stumbles amid a major strategic shift, peers like Howard Hughes Holdings post surprising strength, highlighting the industry's uneven adaptation to a higher-rate environment.
Waste Management's fourth-quarter revenue fell short of Wall Street forecasts, yet the company demonstrated robust margin expansion through disciplined cost management and strategic integration of acquisitions, setting a firm foundation for its 2026 outlook.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
